



Pharmaceuticals Limited

**Registered & Corporate Office :**

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,  
Opp. SBI Executive Enclave, Banjara Hills,

Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 16<sup>th</sup> October, 2025

To  
The Manager,  
Corporate Filings Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001.

The Manager,  
Listing Compliance Department,  
National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051.

**Security Code: 532815**

**Symbol: SMSPHARMA**

Dear Sir/Madam,

**Subject: Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

As per the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors of the Company in its meeting held on 16<sup>th</sup> October, 2025 has approved for change in the security structure relating to the shares held in VKT Pharma Limited (VKT Pharma) an Associate Company.

The Company is holding 38,50,165 equity shares in VKT Pharma, which were already provided pledge as security against the Non-Convertible Debentures (NCDs) issued by VKT Pharma and subscribed by Aventus Finance Private Limited.

As per the request of VKT Pharma, the Company is providing an Undertaking to Exim Bank in connection with the refinancing of existing NCDs, in the form of Non Disposal Undertaking confirming that it shall not sell its shareholding in VKT Pharma without Exim Bank's prior consent.

Further, the details as required under SEBI Circular No SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 with respect to the said surety, is given in Annexure-A to this letter.

Please take the above intimation on your records.

Thanking you

Yours faithfully

**For SMS Pharmaceuticals Limited**

**Thirumalesh Tumma  
Company Secretary**

## Annexure-A

The details as required under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are given as under:

S. No	Particulars	Details
1	Name of party for which such guarantees or indemnity or surety was given;	On behalf of VKT Pharma Private Limited (VKT Pharma) an Associate Company (CIN: U24100TG2006PTC050221) an undertaking is provided to Import and Export Bank of India (Exim Bank) as an assurance.
2	Whether the promoter/ promoter group/ group companies have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	<p>VKT Pharma is an Associate Company and is a related party to the Company. The Company holds 38,50,165 comprising of 34.83% in VKT Pharma as on 31<sup>st</sup> March, 2025.</p> <p>Mr. Ramesh Babu Potluri, Chairman &amp; Managing Director and Mr. Vamsi Krishna Potluri, Executive Director of the Company holds Directorships in VKT Pharma.</p> <p>The Company along with its Promoters holding majority equity shares in VKT Pharma. The transaction is at arm's length basis.</p>
3	brief details of such guarantee or indemnity or becoming a surety viz. brief details of agreement entered (if any) including significant terms and conditions, including amount of guarantee	<p>The Company is holding 38,50,165 equity shares, representing 34.83% of the paid-up share capital of VKT Pharma which were already provided pledge as security against the Non-Convertible Debentures (NCDs) amounting to Rs.130 Crores, issued by VKT Pharma and subscribed by Avendus Finance Private Limited (Avendus Finance).</p> <p>VKT Pharma is obtaining Rupee Term loan an amount of Rs.150 crores from Exim Bank for the purpose of fully refinancing the existing NCDs subscribed by Avendus Finance.</p>

		<p>For that the Company is providing an undertaking to Exim Bank, confirming that the Company shall not dispose of transfer or otherwise encumber its shareholding in held in VKT Pharma, comprising 38,50,165 equity shares (34.83%), without the prior written consent of Exim Bank.</p> <p>Accordingly, there is a change in security structure from exiting of shares with Avendus Finance to an Undertaking in favor of Exim Bank ensuring not dispose of said shares, resulting there is a reduction in the Company's liability.</p> <p>The existing security being replaced with the undertaking on or before 30<sup>th</sup> November 2025.</p>
4	<p>impact of such guarantees or indemnity or surety on listed entity.</p>	<p>The Company agreed to provide undertaking for its holding i.e., 38,50,165 equity shares consisting of 34.83% in VKT Pharma.</p> <p>The Company's liability under the said undertaking shall be limited to the extent of its shareholding in VKT Pharma and the investment value of such shares is Rs. 45.00 Crores.</p>